ORYX GmbH & Co. KG

ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

ORYX to Present Positive Clinical Data for Oncolytic Virus ParvOryx in Combination with Immune Modulators at CIMT Annual Meeting 2018

ORYX: Positive data from Phase I/IIa clinical trial in glioblastoma with oncolytic virus ParvOryx published in peer-reviewed journal, Molecular Therapy

ORYX to present positive clinical data with oncolytic virus ParvOryx in combination with immune activators at the Third CRI-CIMT-EATI-AACR Conference

ORYX reports positive clinical evidence with oncolytic virus ParvOryx in combination with immuno-oncology drugs

ORYX Enrols First Patients in a Dose-Escalating Phase I/IIa Pilot Study with Oncolytic Virus ParvOryx to Treat Metastatic Pancreatic Cancer

ORYX Enrols First Patients in an Additional Phase I Trial with Therapeutic Vaccine VicOryx to Treat HPV-Associated Cancers in Combination with Standard Chemotherapy

ORYX’ Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial to Treat Glioblastoma Multiforme

ORYX Presents Positive Phase I/IIa Data with Therapeutic Vaccine MicOryx to Treat MSI-H Colorectal Cancers at ASCO 2015

ORYX to Present Clinical Data for Therapeutic Vaccine MicOryx in Microsatellite Instable (MSI-H-) Colorectal Cancers at ASCO 2015

ORYX Successfully Completes Phase I/IIa Trial with Therapeutic Vaccine VicOryx to Treat HPV-Associated Cancers

ORYX’ Therapeutic Vaccine MicOryx Successfully Completes Phase I/IIa Trial to Treat MSH-H Colorectal Cancer

ORYX to Present at Sachs European Life Science CEO Forum and Exhibition